Long-Acting Cabotegravir Linked to Low Rates of HIV-1 Detection
|
Evidence of HIV-1 is uncommon among individuals
receiving long-acting cabotegravir (LA CAB) for pre-exposure prophylaxis
(PrEP), although HIV ... |
HIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all. View article...